Clinical trial: An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (NCT04412018)

Eligibility criteria:
Inclusion Criteria:

          1. Positive local SARS-CoV-2 test result within the preceding 72 hours

          2. At least one of the following symptoms

               1. Fever

               2. Cough

               3. Sore throat

               4. Shortness of breath

               5. Myalgia

        Exclusion Criteria:

          1. Individuals currently participating in another interventional trial that will or may
             interfere with the primary outcome

          2. Hospitalized individuals

          3. Individuals who have a current medical condition for which life expectancy is less
             than 3 months

          4. Individuals with a history of acute end-organ injury (e.g. myocardial infarction,
             stroke, hospitalization for acute lung, liver or kidney disease) within the last month

          5. Individuals with active severe liver disease

          6. Individuals with a history of acute or chronic pancreatitis

          7. Women who are pregnant, may be pregnant, are planning on becoming pregnant, or are
             lactating

          8. Women of child-bearing potential who are not using at least one form of highly
             effective (hormonal contraceptives [e.g. combined oral contraceptives, patch, vaginal
             ring, injectables, and implants]; intrauterine device or intrauterine system; tubal
             ligation or whose partner has had a vasectomy) and one effective (barrier methods such
             male condom, female condom, cervical cap, diaphragm, or contraceptive sponge) method
             of contraception

          9. Individuals with a history of hemodynamic instability within past 72 hours including a
             systolic blood pressure of <95 mmHg and/or a diastolic blood pressure of <50 mmHg

         10. Individuals with known hypersensitivity to fish and/or shellfish, or ingredients of
             IPE

         11. Individuals with any other condition which, in the opinion of the Investigator, would
             place the participant at increased risk, preclude obtaining voluntary consent or
             confound the objectives of study

         12. Individuals who are unable to swallow IPE capsules whole
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 75 Years

Patient description (medical language): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient description (patient's own words): I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Does the patient match the trial criteria? 1